Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Careers
Therapeutic Areas
Fibromyalgia
Agitation in Alzheimer's Disease
Biodefense
Major Depressive Disorder
Posttraumatic Stress Disorder
Coronavirus Disease 2019 (COVID-19)
Pipeline
Overview
TNX-102 SL for Fibromyalgia
TNX-601 for Major Depressive Disorder (Depression)
TNX-601 for PTSD
TNX-102 SL for AAD
TNX-801 for Biodefense
TNX-1800 (Coronavirus Vaccine)
Scientific Presentations
Expanded Access Policy
News & Events
Press Releases
Tonix In The News
Investor Presentations
IR Events
Investors
Investor Relations
IR Overview
News / Press Releases
News / Press Releases
Press Releases
Tonix In The News
Email Alerts
Presentations & Events
Investor Presentations
IR Events
Multimedia
Multimedia
Financial Info
Financial Info
Financials
Financial Results
SEC Filings
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Fact Sheet
Fact Sheet
Stock Info
Quote
Charts
Historical Data
Analyst Coverage
Governance
Governance
Board of Directors
Board Committees
Governance Documents
Contact
Sign up for Email Alerts
Tonix Pharmaceuticals Holding Corp. on Facebook
Tonix Pharmaceuticals Holding Corp. on Twitter
Tonix Pharmaceuticals Holding Corp. on LinkedIn
Tonix Pharmaceuticals Holding Corp. on Google Plus
Tonix Pharmaceuticals Holding Corp. RSS
Multimedia
: Multimedia
Home
Investors
Multimedia
Investors
Overview
News / Press Releases
Presentations & Events
Multimedia
Financial Info
SEC Filings
Fact Sheet
Stock Info
Governance
Email Alerts
RSS News Feed
Multimedia
Videos
Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss strategic partnerships in developing vaccines for COVID-19
View Video
Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.
View Video
Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.
View Video
MicroCap Investing Workshop: Potential Solutions for Addressing the Coronavirus Pandemic
View Video
Tonix Pharmaceuticals Discusses Developing COVID-19 Vaccine in Collaboration with Southern Research
View Video
Radio
New York City based pharmaceutical company chooses College Station to manufacture possible coronavirus vaccine
Listen Now
Efforts to Manufacture a COVID-19 Vaccine (Podcast)
Listen Now
